Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1 H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal Tumors.
Kettle, J.G., Anjum, R., Barry, E., Bhavsar, D., Brown, C., Boyd, S., Campbell, A., Goldberg, K., Grondine, M., Guichard, S., Hardy, C.J., Hunt, T., Jones, R.D.O., Li, X., Moleva, O., Ogg, D., Overman, R.C., Packer, M.J., Pearson, S., Schimpl, M., Shao, W., Smith, A., Smith, J.M., Stead, D., Stokes, S., Tucker, M., Ye, Y.(2018) J Med Chem 61: 8797-8810
- PubMed: 30204441 
- DOI: 10.1021/acs.jmedchem.8b00938
- Primary Citation of Related Structures:  
6GQQ, 6GQP, 6GQK, 6GQJ, 6GQM, 6GQL, 6GQO - PubMed Abstract: 
While the treatment of gastrointestinal stromal tumors (GISTs) has been revolutionized by the application of targeted tyrosine kinase inhibitors capable of inhibiting KIT-driven proliferation, diverse mutations to this kinase drive resistance to established therapies ...